Respirerx Pharmaceuticals INC
Market Movers (8-K)
RespireRx Pharmaceuticals issues an open letter to stakeholders summarizing the macro-environment, challenges, accomplishments, disappointments, and plans for 2025.
Worse than expected
Capital raise
Delay expected
Respirerx Pharmaceuticals has amended the terms of its Series I and Series J preferred stock, impacting dividend payouts, voting rights, and liquidation preferences.
RespireRx Pharmaceuticals has engaged Alien Technology Transfer to assist with securing NIH funding for its GABAkines program, focusing on Phase II grant applications.
RespireRx Pharmaceuticals has engaged Alien Technology Transfer for assistance in securing NIH grants for its GABAkines program, while also facing a potential downgrade in its trading market due to disclosure issues.
Worse than expected
Capital raise
RespireRx Pharmaceuticals has received a $1.8 million grant from the Department of Defense to fund a Phase 2 clinical trial of its drug CX1739 for improving bladder function in patients with spinal cord injury.
RespireRx Pharmaceuticals has entered into a purchase agreement for a $100,000 loan and issued warrants to purchase 33,333,333 shares of common stock to Dariusz Nasiek, a member of the company's board of directors, and Sara Nasiek.
Worse than expected
Capital raise